| RNXT | PRESS-RELEASE | neutral | 1/10 | RenovoRx, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| HALO | PRESS-RELEASE | neutral | 1/10 | Halozyme Therapeutics, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| VCEL | PRESS-RELEASE | neutral | 1/10 | Vericel Corporation announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| GEVO | PRESS-RELEASE | bullish | 6/10 | Gevo provided a business update highlighting strong growth in its carbon business, which is expected to deliver over $50 | Oct 22, 2026 |
| SCNX | PRESS-RELEASE | mixed | 5/10 | Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2's $344K, driven by Arbl | Oct 22, 2026 |
| CYRX | PRESS-RELEASE | neutral | 1/10 | Cryoport, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| LENZ | PRESS-RELEASE | neutral | 1/10 | LENZ Therapeutics, Inc. announced it will report its Q3 2026 results on October 29, 2026. | Oct 22, 2026 |
| REPL | PRESS-RELEASE | neutral | 1/10 | Replimune, Inc. announced it will report its fiscal Q2 2027 results on October 28, 2026. | Oct 22, 2026 |
| COLL | PRESS-RELEASE | neutral | 1/10 | Collegium Pharmaceutical, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| KRYS | PRESS-RELEASE | neutral | 1/10 | Krystal Biotech, Inc. announced it will report its Q3 2026 results on November 2, 2026. | Oct 22, 2026 |
| MIRA | PRESS-RELEASE | bullish | 5/10 | MIRA Pharmaceuticals announced positive preclinical results for oral MIRA-55 in a 21-day chronic inflammatory pain model | Oct 22, 2026 |
| SCYX | PRESS-RELEASE | bullish | 7/10 | Scynexis announced positive Phase 1 topline results for IV SCY-247, showing good tolerability and target exposures at 50 | Oct 22, 2026 |
| ABOS | PRESS-RELEASE | neutral | 3/10 | Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug at the CTAD conference | Oct 22, 2026 |
| ABUS | PRESS-RELEASE | bullish | 7/10 | Arbutus Biopharma announced FDA removal of the clinical hold on its IND for AB-101, an oral PD-L1 inhibitor for chronic | Oct 22, 2026 |
| BBIO | PRESS-RELEASE | neutral | 1/10 | BridgeBio Pharma, Inc. announced it will report its Q3 2026 results on October 29, 2026. | Oct 22, 2026 |
| TKNO | PRESS-RELEASE | neutral | 1/10 | Alpha Teknova, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| VNDA | PRESS-RELEASE | neutral | 1/10 | Vanda Pharmaceuticals Inc. announced it will report its Q3 2026 results on October 28, 2026. | Oct 21, 2026 |
| VKTX | PRESS-RELEASE | neutral | 1/10 | Viking Therapeutics, Inc announced it will report its Q3 2026 results on October 28, 2026. | Oct 21, 2026 |
| NATR | PRESS-RELEASE | neutral | 1/10 | Nature's Sunshine Products, Inc. announced it will host a conference call on November 4, 2026 to discuss its Q3 2026 res | Oct 21, 2026 |
| NUVB | PRESS-RELEASE | neutral | 1/10 | Nuvation Bio, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| CTKB | PRESS-RELEASE | neutral | 1/10 | Cytek Biosciences, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| RVMD | PRESS-RELEASE | neutral | 1/10 | Revolution Medicines, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| GNTA | PRESS-RELEASE | bearish | 7/10 | Genenta Science received a Nasdaq deficiency notice for failing to maintain a minimum $1.00 bid price for 30 consecutive | Oct 21, 2026 |
| BCRX | PRESS-RELEASE | neutral | 1/10 | BioCryst Pharmaceuticals, Inc. announced it will report its Q3 2026 results on November 4. | Oct 21, 2026 |
| CYTK | PRESS-RELEASE | neutral | 1/10 | Cytokinetics, Incorporated announced it will report its Q3 results on November 4, 2026. | Oct 21, 2026 |
| ARQT | PRESS-RELEASE | neutral | 1/10 | Arcutis Biotherapeutics, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| SMMT | PRESS-RELEASE | neutral | 5/10 | Akeso announced that its partner Summit Therapeutics (SMMT) initiated a Phase II/III registrational trial (EA2251) for i | Oct 21, 2026 |
| ABT | PRESS-RELEASE | neutral | 4/10 | Abbott reported Q3 2026 EPS of $1.42, a 0.4% beat versus the consensus estimate of $1.41, on revenue of $12.99B (in line | Oct 21, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix reported Q3 2026 group revenue of $245M (+19% YoY), with Precision Medicine revenue up 30% to $201M, and reaffirme | Oct 20, 2026 |
| RNA | PRESS-RELEASE | neutral | 2/10 | Atrium Therapeutics granted inducement stock options and restricted stock units to a new non-executive employee under it | Oct 20, 2026 |
